<DOC>
	<DOCNO>NCT01120093</DOCNO>
	<brief_summary>The present trial conduct assess efficacy mean serial spirometry , safety tolerability three dos aclidinium bromide administer twice day compare previously approve BID drug , formoterol 12 µg , placebo patient moderate severe chronic obstructive pulmonary disease ( COPD ) .after 7 day treatment . Every treatment period 7-days long 5 7-days wash-out period . The trial start run phase 11 17-days duration end follow contact 14-days last treatment dose .</brief_summary>
	<brief_title>Efficacy Safety Three Doses Aclidinium Bromide Compared Placebo Active Comparator Chronic Obstructive Pulmonary Disease ( COPD ) Patients .</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<criteria>1 . Males nonpregnant , nonlactating female age ≥ 40 . 2 . Patients clinical diagnosis stable moderate severe COPD , accord Global Initiative Chronic Obstructive Lung Disease ( GOLD ) guideline : ( http : //www.goldcopd.com ) stable airway obstruction . Postsalbutamol FEV1/FVC &lt; 70 % Screening Visit ( Visit 1 ) ( i.e. , 100xpostsalbutamol FEV1/FVC &lt; 70 % ) . 3 . Current , excigarette smoker smoke history least 10 packyears . 4 . Patient whose FEV1 Screening Visit measure 1015 minute post inhalation salbutamol 30 % &lt; FEV1 &lt; 80 % predict normal value ( i.e. , 100 x Postsalbutamol FEV1/ Predicted FEV1 must &lt; 80 % ≥ 30 % ) . 5 . Female patient least 1 year postmenopausal , surgically sterile ( defined hysterectomy tubal ligation ) , practice medically approve highly effective method contraception . 6 . Patients understand study procedure willing participate study indicate sign informed consent . 1 . History current diagnosis asthma . 2 . Clinically significant respiratory condition COPD time Inform Consent signature 3 . Hospitalisation due COPD exacerbation within previous 3 month . 4 . Signs COPD exacerbation respiratory infection ( include upper respiratory tract ) within previous 6 week . 5 . Clinically significant cardiovascular condition 6 . Presence symptomatic prostatic hypertrophy and/or bladder neck obstruction . 7 . Presence narrowangle glaucoma . 8 . QTcB ) 470 millisecond ECG perform Screening Visit , 9 . Patient maintain regular day/night , waking/sleeping cycle</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>COPD</keyword>
</DOC>